Table 2.

Sequelae, modified Rankin score and Glasgow outcome scale score at 12 months in surviving patients, overall and by N. meningitidis serogroup

Variable	All patients with follow-up at 12 months (N = 71)	Patients with known serogroup and follow-up at 12 months (N = 69)
		B/C/Y (N = 69)	B (N = 36)	C (N = 27)	Y (N = 6)
Persistent headache
Yes	23/70 (32.9%)	23/68 (33.8%)	13/36 (36.1%)	9/26 (34.6%)	1/6 (16.7%)
MCS (SF 12)
Median [IQR]	50.8 [39.6–55.5]	50.9 [40.5–55.7]	51.3 [42.0–57.2]	49.7 [39.6–55.0]	53.0 [35.1–55.0]
PCS (SF12)
Median [IQR]	53.4 [44.3–55.5]	54.1 [42.0–55.5]	52.2 [44.2–55.0]	53.5 [52.6–60.1]	54.1 [42.0–55.5]
Difficulties to concentrate (WHOQOL-BREF)
Not at all able to concentrate	7/70 (10.0%)	7/68 (10.3%)	5/35 (14.3%)	2/27 (7.4%)	1/6 (16.7%)
A little to extremely well	63/70 (90.0%)	61/68 (89.7%)	30/35 (85.7%)	25/27 (92.6%)	5/6 (83.3%)
Satisfied with sleep (WHOQOL-BREF)
Dissatisfied or very dissatisfied	30/70 (42.9%)	29/68 (42.6%)	15/35 (42.9%)	13/27 (48.2%)	1/6 (16.7%)
Neither satisfied nor dissatisfied	11/70 (15.7%)	11/68 (16.2%)	5/35 (14.3%)	5/27 (18.5%)	1/6 (16.7%)
Satisfied or very satisfied	29/70 (41.4%)	28/68 (41.2%)	15/35 (42.9%)	9/27 (33.3%)	4/6 (66.7%)
Resumed professional activity (among those working at baseline)
Yes	48/55 (87.3%)	46/53 (86.8%)	22/26 (84.6%)	21/23 (91.3%)	3/4 (75.0%)
Depressive symptoms (CES-D)
Yes	24/70 (34.3%)	22/68 (32.4%)	12/35 (34.3%)	9/27 (33.3%)	1/6 (16.7%)
Hearing loss (HHI)
Yes*	11/71 (15.5%)	11/69 (15.9%)	2/36 (5.6%)	5/27 (18.5%)	4/6 (66.7%)
Modified Rankin score
Score 0 or 1 (no or low disability)	67/71 (94.4%)	65/69 (94.2%)	35/36 (97.2%)	25/27 (92.6%)	5/6 (83.3%)
Glasgow outcome scale
Good recovery	63/69 (91.3%)	61/67 (91.0%)	32/34 (94.1%)	24/27 (88.9%)	5/6 (83.3%)

*Hearing loss was the only statistically significant difference between serogroups (Fisher exact test, p = 0.002)